So claims interviewees from several companies in this piece from Biopharma-Reporter.com.
Antibody drug conjugates have been hot due to their utlity in delivering a toxic payload to cancer cells without being nearly as damaging to surrounding normal tissues as convention chemotherapeutic agents. And with the approval of a couple of ADC drugs in the past year(s), many players are flcoking to this market. This has caused a surge in activity not only at pharma companies getting into the technology but also a host of CMOs who can product the linkers and conjugated drugs needed.
In just the past couple of weeks, Roche, Novartis, Lilly and Astrazeneca have all annouced investments into this technology. Carbogen Amicis and SAFC have also made additional investments in the space as CMOs for these valuable products. You can expect to keep seeing more activity in this area on the immediate horizon.
Posted by Bruce Lehr Oct 30th 2013.